T1	Participants 62 152	patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.
T2	Participants 462 516	treatment-naive patients with HCV genotype 1 infection
T3	Participants 572 609	Eight hundred and ninety-one patients
